Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Core Scientific (CORZ) EBT (2020 - 2025)

Core Scientific's EBT history spans 6 years, with the latest figure at $216.1 million for Q4 2025.

  • For Q4 2025, EBT rose 181.48% year-over-year to $216.1 million; the TTM value through Dec 2025 reached -$290.7 million, up 77.88%, while the annual FY2025 figure was -$288.0 million, 78.08% up from the prior year.
  • EBT for Q4 2025 was $216.1 million at Core Scientific, up from -$146.5 million in the prior quarter.
  • Across five years, EBT topped out at $576.5 million in Q1 2025 and bottomed at -$936.6 million in Q2 2025.
  • The 5-year median for EBT is -$93.8 million (2023), against an average of -$197.5 million.
  • The largest annual shift saw EBT skyrocketed 740157.69% in 2021 before it crashed 25965.69% in 2022.
  • A 5-year view of EBT shows it stood at $77.0 million in 2021, then crashed by 692.91% to -$456.3 million in 2022, then surged by 57.19% to -$195.4 million in 2023, then plummeted by 35.73% to -$265.2 million in 2024, then skyrocketed by 181.48% to $216.1 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's EBT are $216.1 million (Q4 2025), -$146.5 million (Q3 2025), and -$936.6 million (Q2 2025).